Lunit, Daiichi Sankyo Partner to Support Biomarker Discovery for Two Oncology Programs

Original from: genomeweb

Lunit on Monday said it has started a collaboration with Daiichi Sankyo to use its artificial intelligence-based digital pathology tools to advance translational research and biomarker discovery for two of Daiichi's oncology pipeline programs. 

As part of the collaboration, Seoul, South Korea-based Lunit said that it will use its Lunit SCOPE uIHC tool, which uses AI for quantitative immunohistochemistry (IHC) analysis, and the Lunit SCOPE IO tool, which analyzes the tumor microenvironment for immune phenotyping and spatial analysis.

The insights from the analyses may support clinical trial design for the two programs or biomarker-directed patient stratification for Daiichi's undisclosed oncology programs across multiple cancer types.

"Lunit SCOPE was built to unlock hidden insights from pathology slides — quantifying the tumor microenvironment, predicting molecular profiles, and generating data-rich features to inform trial design," Lunit CEO Brandon Suh said in a statement. "SCOPE uIHC is now enabling the next generation of IHC-based biomarkers. By working with Daiichi Sankyo, we are embedding these capabilities into translational and clinical research, enabling faster biomarker discovery and more precise patient stratification."

Source: Lunit, Daiichi Sankyo Partner to Support Biomarker Discovery for Two Oncology Programs